Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Botanical

or Dissociative

or Migraine medicine

Use the filters below to narrow your results.

None (39) · Amerge (1) · Axert (1) · Cafergot (1) · DHE (1) · DXM (1) · DXO (1) · Frova (1) · Qulipta (1) · Relpax (1) · Reyvow (1) · Spravato (1) · Ubrelvy (1) · Zomig (1)

5-HT1B/1D agonist (4) · NMDA antagonist (3) · 5-HT1B/1D agonist; alpha-adrenergic agonist (2) · CGRP receptor antagonist (2) · Contains LSA (2) · Contains mescaline (2) · NMDA antagonist; sigma receptor agonist (2)

Other values:

None (51) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)

None (51) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

None (51) · 28 mg/device (each dose uses 2 devices) (1)

None (51) · 84 mg per session (1)

None (51) · Intranasal (under direct medical supervision) (1)

None (51) · Within hours of first administration (1)

None (51) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)

None (51) · ~7-12 hours (1)

None (51) · ~48% intranasal (1)

None (51) · Avoid; may cause fetal harm (1)

None (51) · Rx, Schedule III (US). REMS program required. (1)

Showing below up to 53 results in range #1 to #53.

2

2-FDCK

3

4

4-MeO-PCP

7

7-Hydroxymitragynine

A

B

Blue lotus

C

Calea zacatechichi

D

E

F

Frovatriptan

H

I

K

Kava
Kratom

L

Lasmiditan

M

N

O

O-PCE

P

S

2

3

4

7

A

B

C

D

E

F

H

I

K

L

M

N

O

P

S

T

U

X

Y

Z